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Uncontrolled diabetes mellitus results in osmotic diuresis. Diabetic patients have lowered
nitric oxide (NO) which may exacerbate polyuria.We examined how lack of NO affects the
transporters involved in urine concentration in diabetic animals. Diabetes was induced in
rats by streptozotocin. Control and diabetic rats were given L-NAME for 3weeks. Urine
osmolality, urine output, and expression of urea and water transporters and the Na-K-2Cl
cotransporter were examined. Predictably, diabetic rats presented with polyuria (increased
urine volume and decreased urine osmolality). Although metabolic parameters of con-
trol rats were unaffected by L-NAME, treated diabetic rats produced 30% less urine and
osmolality was restored. UT-A1 and UT-A3 were signiﬁcantly increased in diabetic rat inner
medulla.While L-NAME treatment alone did not alter UT-A1 or UT-A3 abundance, absence
of NO prevented the upregulation of both transporters in diabetic rats. Similarly, AQP2
and NKCC2 abundance was increased in diabetic animals however, expression of these
transporters were unchanged by L-NAME treatment of diabetes. Increased expression of
the concentrating transporters observed in diabetic rats provides a compensatory mecha-
nism to decrease solute loss despite persistent glycosuria. Our studies found that although
diabetic-induced glycosylation remained increased, total protein expressionwas decreased
to control levels in diabetic rats treated with L-NAME. While the role of NO in urine con-
centration remains unclear, lowered NO associated with diabetes may be deleterious to
the transporters’ response to the subsequent osmotic diuresis.
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INTRODUCTION
Diabetes mellitus (DM) is one of the leading causes of death in
the United States and is the most common cause of end-stage
renal disease (Centers for Disease Control and Prevention, 2008).
Advancing diabetes results in osmotic diuresis and polyuria plac-
ing the patient at risk for hypovolemic shock. Urea transporters,
UT-A1 andUT-A3,and theNa+-K+-2Cl– cotransporter (NKCC2)
are solute transporters that are not only critical for urine concen-
tration but also control tubule osmotic pressure via regulation of
urea and sodium levels. In the innermedulla (IM), the vasopressin-
sensitive water channel aquaporin 2 (AQP2) is an important
contributor to water reabsorption. The ensuing osmotic diure-
sis and polyuria that occurs with advancing diabetes makes these
transporters of particular interest for our studies.
Evidence suggests that the decline in renal function associated
with advancing diabetes is due to a prolonged state of nitric oxide
(NO) deﬁciency (Huang et al., 2009). NO is generated from nitric
oxide synthase (NOS). There are three distinct isoforms of this
enzyme, all of which are expressed in the kidney: NOS1 (neuronal
or nNOS), NOS2 (inducible or iNOS), and NOS3 (endothelial
NOS or eNOS; Wu et al., 1999). Patients with deleterious poly-
morphisms of NOS3 are more susceptible to developing diabetic
nephropathy (He et al., 2011); an effect that was conﬁrmed in
NOS3 deﬁcient mice with diabetes (Zhao et al., 2006). The decline
in NOS activity in the renal medulla is not however, altered by
glucose-dependent osmotic diuresis alone (Lee et al., 2005).
This does not exclude NO involvement in the urine concentra-
tion mechanism. In fact, the IM, which is the primary site of urine
concentration, expresses all three isoforms of NOS and has the
highest capacity for NO synthesis compared to other nephron seg-
ments (Wu et al., 1999). Similar to uncontrolled DM, transgenic
mice with all three NOS isoforms ablated also display polyuria
(Morishita et al., 2005).
Although not extensive, there is increasing data investigat-
ing the effect of NO on the transporters involved in urine
concentration. NO stimulates a cGMP-mediated pathway that
results in phosphorylation and trafﬁcking of AQP2 to the api-
cal plasma membrane of the inner medullary collecting duct
(IMCD) where the transporter is functional (Bouley et al.,
2005). NO inhibits NKCC2, hindering sodium transport in
the thick ascending limb (Herrera et al., 2009). Urea trans-
port does not appear to be affected by either cGMP or NO
(Nonoguchi et al., 1988). Rather, inhibition of NO produc-
tion increases concentrations of superoxide (O−2 ) which results
in increased urea transport in the IMCD (Zimpelmann et al.,
2003).
Declining NO concentration in the diabetic kidney may
exacerbate the potential for hypovolemic shock by further dis-
turbing the urine concentration mechanism, which is already
compromised by osmotic diuresis. Therefore, the present study
was designed to investigate if the diabetes-driven compen-
satory action of various transporters involved in concentrated
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urine production is compromised in the absence of NO
production.
MATERIALS AND METHODS
ANIMALS
Animal protocols were approved by the Emory University Institu-
tionalAnimal Care andUse Committee.Male SpragueDawley rats
weighing 150–200 g,were allowed free access towater and fed stan-
dard rat chow. Rats were injected (tail-vein) with streptozotocin
(62.5mg/kg) to induce DM, as reported previously (Blount et al.,
2008). Hyperglycemia was veriﬁed 24–48 h after injection using
a Lifescan Ultra II glucometer. Control and DM rats were given
l-NAME (50mg/kg/day) via 5ml of drinking water for 3weeks
following the 4-days after STZ injection. After the rat consumed
the full dose of l-NAME, the regular water bottle was provided for
ad libitum water for the remainder of that 24-h period. This was
repeated each day.
METABOLIC MEASUREMENTS
Rats from all four experimental groups were placed in metabolic
cages for 24 h before sacriﬁce and urine was collected under oil to
prevent evaporation. Urine osmolality was measured on Wescor
5520Vapor Pressure Osmometer (Wescor). Urine urea concentra-
tionwasdeterminedusing InﬁnityUreaReagent fromThermoSci-
entiﬁc (Thermo Fisher Scientiﬁc). Urinary nitrate/nitrite (NOx)
levels were measured in urine as nitric oxide metabolites using a
CaymanFluorometricAssay. Blood glucosewas determined before
sacriﬁce with the glucometer.
SAMPLE PREPARATION AND WESTERN BLOT ANALYSIS
Kidneys were removed and dissected into outer medulla (OM),
base of the IM, and tip of the IM. Tissues were placed into ice-cold
isolation buffer (10mM triethanolamine, 250mM sucrose, pH
7.6, 1μg/ml leupeptin, and 40μg/ml PMSF) and homogenized
with glass homogenizers. SDS was added to a ﬁnal concentra-
tion of 1%, and the samples were sheared with a 25-gage needle.
Homogenates were centrifuged at 8,000 g for 15min, and the
protein in the supernatant fractions was measured by a modi-
ﬁed Lowry method (DC Protein Assay Kit; Bio-Rad). For western
blot analysis, proteins (10–20μg/lane) were ﬁrst size separated by
SDS-PAGE and then electroblotted to polyvinylidene diﬂuoride
membranes (Millipore). Membranes were probed with primary
antibody overnight at 4˚C. Antibodies that were derived and char-
acterized in this laboratory include a COOH-terminal UT-A1
(detects UT-A1 exclusively), NH2-terminal UT-A1 (detects UT-
A1 and UT-A3 simultaneously), AQP2, and NKCC2 were used to
determine the level of respective protein abundances (Blount et al.,
2008). The secondary antibody used for detection was Alexa Fluor
680-linked anti-rabbit IgG (Invitrogen). Signal was detected with
a LI-COR system. Using LI-COR Odyssey software, densitome-
try was determined for each protein. Results reﬂect the ratio of
the densitometry of the detected protein to the densitometry of
β actin where β actin (antibody from Sigma Aldrich) served as a
loading control.
STATISTICAL ANALYSIS
Values are SE from each experimental groupwhere n = 5. Densito-
metry ratios were calculated based on β actin loading controls. The
densitometries from each group of animals were averaged and the
data were presented as means± SE for the percent change from
the control value. To test for statistical signiﬁcance between the
multiple groups, we used an ANOVA followed by Newman–Keuls
test. The criterion for statistical signiﬁcance was p < 0.05.
RESULTS
ADMINISTRATION OF L-NAME ALTERS METABOLIC PROGRESSION OF
DIABETES
Age-matched male Sprague Dawley rats from the following exper-
imental groups were individually placed in metabolic cages to
monitor physiological changes for 24 h: (1) control rats, (2) rats
treated with l-NAME, (3) DM rats, and (4) DM rats treated with
l-NAME (Table 1). DM animals showed elevated blood glucose
at the time of sacriﬁce conﬁrming hyperglycemia. l-NAME did
not change blood glucose levels of either control or DM animals.
DM rats had a higher urine output and lower urine osmolality
than control animals. l-NAME-treated animals did not have a sig-
niﬁcant increase in urine volume compared to control animals
however, urine osmolality was signiﬁcantly decreased. l-NAME
treatment of DM animals decreased urine output compared to
untreated DM rats. These animals still produced a greater vol-
ume of urine than the control animals. Although urine osmolality
of l-NAME-treated DM animals was higher than untreated DM
rats, the reported value did not reach signiﬁcance. Rats treated
with l-NAME had no change in urine urea however DM rats had
a signiﬁcantly lower urine urea corresponding with the osmo-
lality decrease. l-NAME treatment of DM rats slightly increased
urine urea.While this change was not signiﬁcant fromDM values,
the amount of urine urea was not different than control rats. To
reﬂex the amount of nitric oxide excreted in the urine, we mea-
suredurinary nitrate/nitrite (NOx) levels.NOx levelswere lowered
68% in rats treated with l-NAME when compared to control ani-
mals, conﬁrming that l-NAME was inhibiting the production of
nitric oxide. Diabetic rats also had lowered urineNOx levels (77%)
compared to control rats. This is not surprising given thatNOcon-
centration is lower in kidneys of STZ-injected diabetic rats (Palm
et al., 2005). l-NAME treatment of DM rats reduced the already
lowered levels of NOx in the urine slightly.
ADMINISTRATION OF L-NAME REDUCED THE COMPENSATORY
UPREGULATION OF UREA TRANSPORTERS NORMALLY OBSERVED
WITH DM
UT-A1, a glycoprotein, is expressed in both the papilla and IM
base. Although the functional difference remains a mystery, abun-
dance of the two glycoproteins of UT-A1 (117 and 97-kDa) differ
based on tissue location. Western analysis of control rats detected
both glyco-forms of UT-A1 in the IM tip (Figure 1A) and the
predominant 97-kDa form in IM base (Figure 1D). l-NAME
treatment alone did not change the total protein abundance of
UT-A1 in either section of the IM nor did the inhibition of NO
change the glycosylation state (Figure 1). UT-A1 expression was
signiﬁcantly upregulated in both the IM tip and base of diabetic
rats. This was largely attributable to increased expression of the
117-kDa form (Figures 1C,F). Diabetic rats treated with l-NAME
did not have a signiﬁcant increase in total UT-A1 protein abun-
dance (97- or 117-kDa) in the IM tip (Figures 1B,C). In the IM
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Table 1 | Effects of L-NAME administration on control and diabetic rats.
Blood glucose (mg/dl) Urine volume (ml/24h) Urine urea (mmol) Urine osmolality (mmol/kg) Urine NOx (μM)
Control 82.3±5.7† 19.7±2.5† 172.6±25† 1535±47† 545±35†
Control+L-NAME 70.6±3.4† 24.8±3.2† 161.4±25† 1225±35*† 176±23*
DM 266±11* 176±10* 76.1±8.2* 943±22* 127±3.7*
DM+L-NAME 301±23* 126±20*† 93.5±14 1083±63* 115±34*
*p>0.05 compared to control.
†p>0.05 compared to DM.
Newman–Keuls test.
FIGURE 1 | Upregulation of UT-A1 in diabetes is blunted by NO inhibition.
Shown is a representative western blot of inner medulla (IM) tip (A) and base
(D) probed for UT-A1 where each lane represents one rat. Densitometry was
determined for the 97-kDa (B) and 117-kDa glyco-forms (C) in IM tip and the
97-kDa (E) and 117-kDa glyco-forms (F) in IM base. The experimental
conditions were performed 5 times (n=5) where there were 5 animals per
experimental group in each cohort. In total, 25 animals per experimental group
were analyzed. *p <0.05 compared to control, †p <0.05 compared to DM.
base of l-NAME-treated diabetic animals, 97-kDa UT-A1 abun-
dance was statistically increased when compared to control rats
but expression of this glycoprotein was also signiﬁcantly decreased
compared to diabetic rats (Figure 1E). l-NAME treatment of dia-
betic animals did inhibit induction of the 117-kDa form of UT-A1
however the amount of 117-kDa protein is ∼3.5-fold over basal
levels (Figure 1F).
UT-A3 is also a glycoprotein that is found predominantly in
the papilla in the IM. This transporter is distinguished as multiple
glyco-forms ranging from 45- to 65-kDa (Blount et al., 2008) as
detected in control rats (Figure 2A). Rats treated with l-NAME
did not demonstrate a change in UT-A3 glycoprotein abundance
(Figures 2B,C). Corroborating previous reports (Blount et al.,
2008), UT-A3 abundance was increased in DM rats (Figure 2B).
The increased protein abundance of UT-A3 is due to increased
glycosylation of the upper form of the protein (Figure 2B)
whereas induction of diabetes had no effect on the 45-kDa UT-A3
(Figure 2C). l-NAME treatment of the DM rats prevented the
compensatory increase in UT-A3 abundance (Figure 2). Interest-
ingly, l-NAME treatment of diabetic rats signiﬁcantly reduced the
45-kDa glycosylated form of UT-A3 (Figure 2C).
L-NAME REDUCED THE DM-INDUCED UPREGULATION OF THE WATER
CHANNEL, AQP2
AQP2 is expressed as glycosylated (40–46-kDa) andunglycosylated
(29-kDa) proteins (Nejsum et al., 2001) as observed in control
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FIGURE 2 | Upregulation of UT-A3 in diabetes is blunted by NO
inhibition. Presented is a representative western blot of IM tip (A) probed
for UT-A3. Densitometry was determined for all the 65-kDa smear (B) and
45-kDa glyco-form (C) in the IM tip. The experimental conditions were
performed ﬁve times (n=5) where there were ﬁve animals per
experimental group in each cohort. In total, 25 animals per experimental
group were analyzed. *p <0.05 compared to control, †p <0.05 compared
to DM.
rat IM tip and base (Figures 3A,D). l-NAME treatment did not
affect AQP2 expression in the papilla but did lower protein lev-
els in the IM base (Figures 3B,E). Glycosylated AQP2 protein
levels were signiﬁcantly increased in both the tip and base of
diabetic IM (Figures 3B,E); however, the unglycosylated form of
AQP2 was not altered in response to diabetes in either IM tip or
base (Figures 3C,F). In the IM tip of diabetic animals, l-NAME
treatment had no effect on the unglycosylated AQP2 expression
(Figure 3C) but did reduce the glycosylated AQP2 abundance
to basal level (Figure 3B). l-NAME treatment of DM animals
lowered glycosylated AQP2 levels in the IM base compared to
DM animals (Figure 3E) but did not alter unglycosylated AQP2
abundance (Figure 3F).
NKCC2 WAS INCREASED IN DM ANIMALS BUT EXPRESSION LEVELS
WERE UNAFFECTED BY L-NAME
NKCC2 was detected at 150-kDa in the OM dissected from
rat kidney (Figure 4A). Rats treated with l-NAME did not
have any alteration in NKCC2 protein abundance (Figure 4B).
STZ-treatment signiﬁcantly increased NKCC2 levels (Figure 4B).
l-NAME treatment did not signiﬁcantly change the increased
NKCC2 abundance in DM rats.
DISCUSSION
The goal of this study was to determine how declining NO in the
diabetic kidney affects the already compromised urine concen-
trating mechanism. Using STZ-induced diabetic rats, we found
that l-NAME-mediated inhibition of NO alleviated the polyuria
observed in untreated diabetes. l-NAME treatment alone did not
alter basal levels of blood or urine glucose suggesting that l-NAME
treatment of the DM kidney does not improve polyuria by alter-
ing glucose-dependent osmotic diuresis but by other mechanisms,
including differential expression of the concentrating transporters
UT-A1, UT-A3, and AQP2.
The effect of untreated DM on urea transporter expression and
function in the IM has been extensively investigated (Kim et al.,
2003, 2005; Blount et al., 2008). Collectively, these studies have
found that DM induces an increase in both UT-A1 and UT-A3
protein abundance in an attempt to restore inner medullary inter-
stitial urea, which is disrupted in the advancement of the disease.
Our results present the novel ﬁnding that diabetic rats treated
with l-NAME did not have the compensatory increase in UT-
A1 or UT-A3 expression. Previous work has shown that UT-A1
protein abundance increases during osmotic diuresis whenever
urinary urea decreases in order to continuously transport urea
to the interstitium (Kim et al., 2005). Although DM resulted in
decreased urea as a urinary solute in this study, l-NAME treat-
ment of DM rats increased the amount of urea in urine, possibly
explaining the dampened increase of urea transporter proteins in
the face of DM.
Early work demonstrated that both glycoproteins of UT-A1
are equally upregulated in the papilla in response to chronic dia-
betes; however, increased protein expression of UT-A1 in the IM
base of diabetic rats was mainly due to an increase in the 117-
kDa form (Kim et al., 2003). Our ﬁndings are in agreement;
total UT-A1 expression was signiﬁcantly upregulated throughout
the IM of diabetic rats, particularly in the IM base. Despite the
decrease in overall protein expression, l-NAME-treated DM ani-
mals still had an increase in the 117-kDa glycoprotein. Recently,
Chen et al. (2011) determined that the 117-kDa UT-A1 was the
mature glycosylation form of the transporter. Furthermore, the
researchers found that the 117-kDa form is associated with lipid
rafts. This localization of 117-kDa UT-A1 into lipid rafts was
increased in response to diabetes. Although not proven to be the
mature glycosylation form of UT-A3, we found that uncontrolled
diabetes increased the upper 65-kDa glycosylated form while the
lower, 45-kDa form remained unchanged. Hyperglycemia has
been linked to increased glycosylation of a variety of proteins
(Martin et al., 2006). It is possible that uncontrolled diabetes
increases UT-A1 and UT-A3 membrane trafﬁcking by changing
the glycosylation state, which facilitates lipid raft targeting; how-
ever, we did not examine altered cellular location in our studies.
Although hyperglycemia-induced glycosylation may account for
the increased presence of the 117-kDa form of UT-A1 and 65-kDa
form of UT-A3 independent of nitric oxide, it does not explain the
dampened total protein abundance. Further studies addressing the
function of the urea transporter glycosylation states and lipid rafts
in diabetes will need to be pursued to completely elucidate this
question.
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FIGURE 3 | Upregulation of glycosylated AQP2 in diabetes is blunted by
NO inhibition. Displayed is a representative western blot of IM tip (A) and
base (D) probed for AQP2. Densitometry was determined for the
glycosylated (B) and unglycosylated forms (C) in the IM tip as well as the
glycosylated (E) and unglycosylated forms (F) in the IM base. To prevent
saturation of bands, the blot was scanned at a lighter intensity to measure
glycosylated AQP2 (A,D) and at a higher intensity to measure the
unglycosylated AQP2 (A,D) however, images are gleaned from the same
representative western blot. The experimental conditions were performed
ﬁve times (n=5) where there were ﬁve animals per experimental group in
each cohort. In total, 25 animals per experimental group were analyzed.
*p <0.05 compared to control, †p <0.05 compared to DM.
Investigation of AQP2 revealed that l-NAME treatment did
not affect AQP2 expression in the papilla but did lower protein
levels in the IM base. This corresponds to studies that docu-
mented decreasedAQP2 expression in the IM of rats orally treated
with l-NAME for 6weeks (Albertoni Borghese et al., 2007). We
found that glycosylated AQP2, but not unglycosylated AQP2, is
upregulated in response to diabetes which is in agreement with
previously published reports (Nejsum et al., 2001; Satake et al.,
2010). Although not investigated in this study, uncontrolled dia-
betes can increase vasopressin plasma levels (Trinder et al., 1994;
Iwasaki et al., 1996; Bardoux et al., 1999). This could explain the
increase in AQP2 expression in response to diabetes in that vaso-
pressin can upregulate AQP2 protein levels at a transcriptional
level (Nielsen et al., 2002). In our study, DM animals treated
with l-NAME had no compensatory increase in AQP2 expres-
sion. Nitric oxide synthase inhibition by l-NAME has been shown
to inhibit vasopressin release (Mornagui et al., 2010), perhaps
explaining the lowered levels of AQP2 expression the treated DM
animals.
In our studies, l-NAME treatment had no effect on NKCC2
expression. These ﬁndings do not corroborate with other studies
which observed an increase of NKCC2 abundance in response to
l-NAME (Kim et al., 2006; Wangensteen et al., 2006; Riazi et al.,
2009). These studies differ from ours in that the rats were sub-
jected to l-NAME for 4–8weeks whereas the rats in our study
were treated with l-NAME for 3weeks. In addition, we used a
lower concentration of l-NAME during treatment compared to
the other studies. While these may be minor factors, alterations
in NKCC2 levels have been shown to be time dependent in other
animal models (Kim et al., 2003). NKCC2 protein abundance was
upregulated in the OM of DM rats. Increased NKCC2 expres-
sion likely increases sodium reabsorption and, through counter-
current multiplication, increases urine concentration. l-NAME
did not alter the elevated expression of NKCC2 in DM animals.
Given the likelihood that treatments of l-NAME longer than
3weeks increases NKCC2 expression, it would be interesting to see
if longer treatment periods ampliﬁes the DM-induced compen-
satory upregulation of the transporter. NO stimulates production
of cGMP which has been shown to decrease surface NKCC2 lev-
els thus rendering the transporter inactive (Ares et al., 2008). It is
possible that the l-NAME used in our studies prevents the syn-
thesis of cGMP allowing NKCC2 to accumulate at the plasma
membrane where it is active in the DM animals contributing
to the reduction of polyuria in the l-NAME-treated DM rats.
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FIGURE 4 | NO inhibition does not affect NKCC2 expression. Observed
is a representative western blot of outer medulla (A) probed for NKCC2.
Densitometry was determined (B). The experimental conditions were
performed ﬁve times (n=5) where there were ﬁve animals per
experimental group in each cohort. In total, 25 animals per experimental
group were analyzed. *p <0.05 compared to control, †p <0.05 compared
to DM.
This hypothesis would need to be conﬁrmed with localization
experiments.
Long-term treatment of rats with l-NAME can reduce
medullary blood ﬂow resulting in a major effect on sodium and
water homeostasis and promoting the development of hyperten-
sion in these animals (Cowley et al., 1995). We did not measure
blood pressure in our experimental animal groups however, it is
probable that l-NAME-treated animals were hypertensive. Thus,
l-NAME-induced hypertension and not NOS inhibition may be
the explanation for the attenuated expression of the concentrated
transporters in l-NAME-treated DM animals. Protein abundance
of these transporters has been examined in other animal mod-
els of hypertension (Klein et al., 2006). In these models UT-A1,
AQP2, and NKCC2 were all downregulated. In our l-NAME-
treated animals, which should mimic these hypertension models,
we did not see a change in transporter expression levels. Although
the contribution of hypertension cannot be ruled out, because the
expected decrease of UT-A1,AQP2, andNKCC2was not observed,
we assume that a majority of the l-NAME effects in our study is
due to NOS inhibition and not hypertension.
Several reports have shown that administration of l-NAME
to STZ-treated rats reduces the renal hyperﬁltration that occurs
with uncontrolled diabetes (Ito et al., 2001; Brands et al., 2004).
Although it seems plausible that urine ﬂow rates may contribute
to urea transporter and AQP2 expression, studies have found that
protein levels of these transporters are not responsive to increased
urine ﬂow rate or loss of medullary hypertonicity (Marples et al.,
1998). For instance, animals with lithium-induced nephrogenic
diabetes insipidus produce a large 24-h urine volume but have
reduced AQP2, UT-A1, and UT-A3 expression rather than the
increased expression observed in the DM model (Blount et al.,
2010). Thus, we believe that the reduction of urine output in
l-NAME-treated rats is not the explanation for the decrease in
transporter expression.
Interpretation of our ﬁndings are complicated by conﬂicting
reports of the roles of NO and NOS in the diabetic kidney. Col-
lectively, studies indicate that expression of all isoforms of NOS is
increased in the IM of STZ-induced diabetes although by possibly
different mechanisms (Lee et al., 2005). Increased NOS1 expres-
sion was found to be due to high blood glucose but not glycosuria
whereas increased NOS3 activity in the IMCD is attributed to
sheer stress stimuli due to the high urine ﬂow associated with dia-
betes (Lee et al., 2005). Despite reports of localized increases of
NO production in the IMCD (Choi et al., 1999), we observed a
decrease in NO in the urine of diabetic rats. Since urinary NOx
is an indicator of total NO production in an animal (Wang et al.,
2011), we can conclude that the reported increase in NOS activ-
ity in the IMCD is not sufﬁcient to prevent an overall decrease
in total body NO production. NO concentration in the kidney
changes with advancing diabetes (Komers and Anderson, 2003).
In early diabetes, there is an excess of NO which likely contributes
to renal hyperﬁltration and hyperperfusion. Hyperﬁltration was
shown to be reversed via l-NAME administration to STZ-injected
rats (Levin-Iaina et al., 2011). Advanced stages of diabetes lower
NO levels in the kidney which contribute to the declining renal
function. Urinary nitrite/nitrate excretion is decreased in rodent
models of chronic diabetes (Trachtman et al., 2002) suggesting
that the animal model used in these studies resembles later stages
of diabetes.
The initial increase of NOS isoforms in diabetes may further
complicate disease progression. Each isoform of NOS requires
ﬁve cofactors/prosthetics to produce NO from l-arginine. Reduc-
tion of these cofactors and/or substrate, frequently observed in
advanced diabetes, leads to the uncoupling of NOS resulting in the
synthesis of O−2 instead of NO (Forbes et al., 2008). Increased con-
centrations of O−2 in diabetic animals could explain the increased
expression of the urea transporters in the diabetic IM given that
urea permeability is increased by O−2 (Zimpelmann et al., 2003). In
our studies,l-NAMEmay be exerting the observed effect by reduc-
ing the elevated O−2 levels in diabetic animals. Although in some
reports, administrationof l-NAMEsigniﬁcantly increasedO−2 lev-
els (Usui et al., 1999; Heiman and Allen-Gipson, 2000). It would
therefore be interesting to examine the fate of the concentrating
transporters in diabetic animals that were treated with l-NAME
and proven O−2 production inhibitors such as allopurinol, ebselen,
and NAC.
Reports indicate that diabetes affects the individual isoforms
of NOS differently. Diabetic mice lacking NOS3 do not have
severe oxidative stress and tubulointerstitial ﬁbrosis compared
to control, diabetic mice (Wang et al., 2011). However, dia-
betic nephropathy was more severe in STZ-induced diabetic
NOS2 knockout mice than STZ-injected wild type mice (Tra-
chtman et al., 2002). It has been suggested that cellular distri-
bution of NOS isoforms may explain conﬂicting effects. In the
IM, NOS1 is largely cytosolic while NOS2 and NOS3 levels are
more associated with membrane enriched fractions (Lee et al.,
2005). Cytosolic NOS activity, due to NOS3, is increased early-
onset diabetes (Lee et al., 2005). l-NAME inhibits all isoforms
of NOS thus we were unfortunately not able to address the
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impact that individual NOS isoforms have on diabetes-induced
polyuria.
In conclusion, we found that inhibition of NOS activity can
reduce the advancing polyuria associated with diabetes. Uncon-
trolled diabetes increased total protein abundance of the urine
concentrating transporters, UT-A1, UT-A3, and AQP2 by increas-
ing glyco-forms of the transporters in a compensatory man-
ner. While not altering the enhanced glycosylation state of these
transporters, inhibition of NO inDMprevented the increased total
expression of these transporters.
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